Compare · GKOS vs RMD
GKOS vs RMD
Side-by-side comparison of Glaukos Corporation (GKOS) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.86B, about 3.1x GKOS ($9.21B).
- Over the past year, GKOS is up 60.3% and RMD is down 22.9% - GKOS leads by 83.1 points.
- GKOS has been more active in the news (16 items in the past 4 weeks vs 7 for RMD).
- Both have 25 recent analyst ratings on file.
- Company
- Glaukos Corporation
- ResMed Inc.
- Price
- $156.81+0.90%
- $198.99-1.86%
- Market cap
- $9.21B
- $28.86B
- 1M return
- +23.03%
- +2.60%
- 1Y return
- +60.29%
- -22.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 16
- 7
- Recent ratings
- 25
- 25
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest GKOS
- SVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,550,000 worth of shares (10,000 units at $155.00) as part of a pre-agreed trading plan (SEC Form 4)
- SVP & CHIEF FINANCIAL OFFICER Thurman Alex R. exercised 10,000 shares at a strike of $38.68 and sold $1,500,000 worth of shares (10,000 units at $150.00) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $99,567 worth of shares (716 units at $139.06) as part of a pre-agreed trading plan, decreasing direct ownership by 0.81% to 87,634 units (SEC Form 4)
- Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29
- H.C. Wainwright initiated coverage on Glaukos with a new price target
- CHAIRMAN & CEO Burns Thomas William covered exercise/tax liability with 4,059 shares, decreasing direct ownership by 6% to 68,967 units (SEC Form 4) to satisfy withholding obligation
- PRESIDENT & COO Gilliam Joseph E covered exercise/tax liability with 1,056 shares, decreasing direct ownership by 1% to 72,363 units (SEC Form 4) to satisfy withholding tax
- CHIEF DEVELOPMENT OFFICER Navratil Tomas covered exercise/tax liability with 483 shares, decreasing direct ownership by 0.54% to 88,350 units (SEC Form 4) to satisfy withholding tax
- Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis
- Amendment: SEC Form 4 filed by Director Foley Mark J
Latest RMD
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)